12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation

Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), remains one of the leading causes of direct maternal mortality and severe maternal morbidity in high-resource nations. Pregnancy induces a profound prothrombotic state that persists into the puerperium. Understanding the unique anatomical, physiological, and pharmacological considerations of anticoagulation is vital for maternal-fetal survival.

---

1. Pathophysiology: Virchow's Triad in Pregnancy

The baseline risk of VTE is increased 4- to 5-fold during pregnancy compared to non-pregnant women of reproductive age. In the postpartum period—particularly the first 6 weeks—this relative risk skyrockets to 20- to 80-fold, with the highest peak incidence occurring in the first 1 to 2 weeks after delivery.

+---------------------------------------------------------------------------------------------------+
|                         VIRCHOW'S TRIAD: PREGNANCY-SPECIFIC MECHANISMS                            |
|                                                                                                   |
|  1. HYPERCOAGULABILITY (Physiological Hemostatic Adaptation):                                     |
|     • Marked increase in procoagulant clotting factors: Fibrinogen (Factor I, rises 50-100%),    |
|       Factor VII, Factor VIII, Factor X, and von Willebrand factor (vWF).                         |
|     • Significant reduction in natural endogenous anticoagulants: Free Protein S levels drop by   |
|       40-60%; acquired activated protein C (APC) resistance develops in 2nd and 3rd trimesters.   |
|     • Impairment of fibrinolysis: Placental production of Plasminogen Activator Inhibitor-1 (PAI-1)|
|       and PAI-2 dramatically blunts endogenous clot lysis until placental expulsion.              |
|                                                                                                   |
|  2. VENOUS STASIS (Mechanical & Hormonal Flow Impairment):                                        |
|     • Progesterone-mediated venodilation increases venous capacitance and decreases vascular tone.|
|     • Mechanical compression: The enlarging gravid uterus compresses the inferior vena cava (IVC) |
|       and common iliac veins starting at 16-20 weeks, halving lower extremity venous flow velocity|
|       and causing profound stasis.                                                                |
|                                                                                                   |
|  3. VASCULAR ENDOTHELIAL INJURY:                                                                  |
|     • Endothelial shear stress and microscopic vascular damage occur during labor, uterine        |
|       contractions, vaginal lacerations, instrumental delivery, and cesarean hysterotomy.        |
+---------------------------------------------------------------------------------------------------+

---

2. Clinical Presentation & Anatomical Asymmetry

Anatomical Predilection of Pregnancy-Associated DVT

• Left-Leg Predominance (80% to 90%): In non-pregnant populations, DVTs are distributed equally between legs. In pregnancy, the vast majority occur on the left side due to May-Thurner anatomy: the right common iliac artery crosses anteriorly over the left common iliac vein, compressing it against the lumbar spine. When the gravid uterus rests against these vessels, left-sided iliofemoral venous stasis is dramatically accentuated.
• Proximal & Iliofemoral Predominance (70% to 80%): Unlike non-pregnant individuals (where calf DVTs predominate), pregnancy-related thromboses are predominantly located in the iliofemoral, external iliac, and common femoral veins. Proximal iliofemoral DVTs carry a substantially higher risk of embolization and massive PE.

Clinical Manifestations

• DVT: Acute, unilateral lower extremity pain, swelling, warmth, tenderness, and erythema. A difference in calf or thigh circumference >2 cm between limbs is clinically significant. Pelvic or isolated iliac vein thrombosis may present atypically as vague lower abdominal, back, buttock, or flank pain with minimal leg swelling.
• PE: Sudden-onset dyspnea (most common symptom, >80%), pleuritic chest pain, tachypnea (respiratory rate >20 breaths/min), tachycardia (heart rate >100 bpm), apprehension, cough, hemoptysis, syncope, or acute desaturation.

---

3. Diagnostic Algorithm for Suspected DVT and PE

The Pitfall of D-Dimer in Pregnancy

Plasma D-dimer levels rise physiologically throughout normal pregnancy, beginning in the first trimester and peaking at delivery. Consequently, standard non-pregnant D-dimer cutoffs (<500 mcg/L) have very low specificity and a high false-positive rate. While a negative highly sensitive D-dimer with low clinical pretest probability (e.g., using pregnancy-adapted algorithms like the YEARS criteria) can occasionally exclude VTE, imaging must not be delayed or omitted in patients with moderate-to-high clinical suspicion.

+---------------------------------------------------------------------------------------------------+
|                         STEP-BY-STEP DVT DIAGNOSTIC WORKUP                                        |
|                                                                                                   |
|  STEP 1: BEDSIDE COMPRESSION ULTRASOUND (CUS) WITH COLOR DOPPLER                                  |
|  • Perform complete whole-leg compression ultrasound (common femoral, femoral, popliteal, calf).  |
|  • Diagnostic Criterion: Inability to fully compress the venous lumen under transducer pressure.  |
|                                                                                                   |
|  STEP 2: INTERPRETATION & ACTION                                                                  |
|  • Positive CUS: Confirm diagnosis; immediately initiate therapeutic anticoagulation.             |
|  • Negative CUS with Low Clinical Suspicion: Withhold anticoagulation; observe.                   |
|  • Negative CUS with High Clinical Suspicion or Iliac Vein Symptoms (Groin/Pelvic Pain):          |
|    - Pelvic/iliac veins are difficult to visualize on standard transabdominal ultrasound.         |
|    - Options: Perform Doppler interrogation of iliac vessels / Magnetic Resonance Venography      |
|      (MRV without gadolinium) OR repeat serial CUS in 3 to 7 days.                                |
|    - If high suspicion persists, empiric therapeutic LMWH should be administered pending imaging. |
+---------------------------------------------------------------------------------------------------+

Pulmonary Embolism Diagnostic Strategy & Radiation Dosimetry

When PE is suspected, diagnostic imaging must never be withheld due to fetal radiation concerns. The fetal radiation dose from both Ventilation-Perfusion (V/Q) scintigraphy (<0.1 to 0.5 mGy) and CT Pulmonary Angiography (CTPA, <0.05 to 0.1 mGy) is orders of magnitude below the established 50 mGy threshold for fetal teratogenesis, oncogenesis, or microcephaly.

+---------------------------------------------------------------------------------------------------+
|                         EVIDENCE-BASED PE IMAGING SELECTION                                       |
|                                                                                                   |
|  INITIAL STEP: CHEST X-RAY (CXR) WITH ABDOMINAL SHIELDING                                         |
|  • Purpose: Identify alternative causes (pneumonia, pneumothorax, pulmonary edema) and guide      |
|    subsequent advanced imaging modality.                                                          |
|                                                                                                   |
|  IF CXR IS NORMAL:                                                                                |
|  • Perform Ventilation-Perfusion (V/Q) Scan (or perfusion-only scan with reduced isotope dose).   |
|  • Rationale: In the setting of a clear CXR, V/Q scan has a high diagnostic yield (>90%          |
|    definitive normal or high-probability), delivers lower maternal breast radiation dose (0.5 to  |
|    1.5 mGy) compared to CTPA, and carries minimal fetal dose (<0.5 mGy).                          |
|                                                                                                   |
|  IF CXR IS ABNORMAL (Atelectasis, Infiltrate, Effusion, Cardiomegaly):                            |
|  • Perform CT Pulmonary Angiography (CTPA).                                                       |
|  • Rationale: An abnormal CXR results in an indeterminate/nondiagnostic V/Q scan. CTPA allows    |
|    direct visualization of pulmonary artery filling defects and alternative lung pathology.      |
|  • Maternal Breast Radiation: CTPA delivers 10 to 20 mGy to maternal breast tissue (a slight     |
|    lifetime relative risk increase for breast malignancy); use bismuth breast shields and low-   |
|    kVp protocols where available.                                                                 |
+---------------------------------------------------------------------------------------------------+

---

4. Anticoagulation Strategies & Pharmacology

First-Line Agent: Low-Molecular-Weight Heparin (LMWH)

LMWH (e.g., Enoxaparin, Dalteparin, Tinzaparin) is the gold standard for antepartum and postpartum anticoagulation because it does not cross the placenta, carries no risk of fetal teratogenicity or bleeding, and offers superior bioavailability, predictable pharmacokinetics, and a lower risk of heparin-induced thrombocytopenia (HIT) and osteoporosis compared to unfractionated heparin (UFH).

Monitoring Note: Due to increased renal clearance and expanded plasma volume in pregnancy, twice-daily therapeutic LMWH (1 mg/kg q12h) is preferred over once-daily dosing to maintain consistent therapeutic levels.

---

5. Peripartum Anticoagulation & Neuraxial Anesthesia Guidelines

The placement of spinal, epidural, or combined spinal-epidural (CSE) anesthesia in an anticoagulated patient carries the catastrophic risk of spinal or epidural hematoma, which can cause permanent paraplegia. Adherence to strict withholding intervals (endorsed by the American Society of Regional Anesthesia and Pain Medicine [ASRA] and the Society for Obstetric Anesthesia and Perinatology [SOAP]) is mandatory.

+---------------------------------------------------------------------------------------------------+
|                         NEURAXIAL ANESTHESIA WITHHOLDING & TIMING RULES                           |
|                                                                                                   |
|  PRE-PROCEDURAL WITHHOLDING INTERVALS BEFORE NEURAXIAL PLACEMENT:                                 |
|  • Prophylactic LMWH (e.g., Enoxaparin 40 mg SC daily):                                          |
|    - Withhold for AT LEAST 12 HOURS prior to needle placement or catheter manipulation.           |
|  • Therapeutic LMWH (e.g., Enoxaparin 1 mg/kg q12h or 1.5 mg/kg q24h):                           |
|    - Withhold for AT LEAST 24 HOURS prior to needle placement or catheter manipulation.           |
|    - Elective Transition: At 36-37 weeks of gestation, patients on therapeutic LMWH are often      |
|      transitioned to therapeutic subcutaneous or IV UFH to facilitate flexible delivery timing.   |
|  • Therapeutic Intravenous UFH Infusion:                                                          |
|    - Discontinue infusion AT LEAST 4 TO 6 HOURS prior to neuraxial placement.                     |
|    - MANDATORY: Document a confirmed normal aPTT before proceeding with neuraxial puncture.      |
|  • Therapeutic Subcutaneous UFH (e.g., 10,000 units SC q12h):                                     |
|    - Withhold for AT LEAST 12 HOURS; verify normal aPTT.                                          |
|                                                                                                   |
|  POST-PROCEDURAL RESUMPTION OF ANTICOAGULATION:                                                   |
|  • Epidural Catheter Removal:                                                                     |
|    - Withhold LMWH for at least 12 hours (prophylactic) or 24 hours (therapeutic) before catheter |
|      removal.                                                                                     |
|  • Resumption After Catheter Removal:                                                             |
|    - Prophylactic LMWH: May be restarted >=4 hours after catheter removal (and >=4-6h post-birth).|
|    - Therapeutic LMWH: May be restarted >=4 hours after catheter removal, AND at least 24 hours   |
|      after cesarean delivery (or >=12 hours after uncomplicated vaginal delivery) with hemostasis.|
+---------------------------------------------------------------------------------------------------+

---

6. Massive Pulmonary Embolism & Hemodynamic Collapse

Massive PE in pregnancy is defined as acute PE accompanied by sustained hypotension (systolic blood pressure <90 mmHg for >=15 minutes or requiring inotropic/vasopressor support), profound shock, or cardiac arrest, not caused by hypovolemia, sepsis, or arrhythmia.

Resuscitation & Emergency Intervention Protocol

1. Immediate Resuscitation:
   • Administer high-flow 100% oxygen; perform endotracheal intubation if respiratory failure ensues.
   • Avoid aggressive fluid loading! The right ventricle (RV) is acutely dilated and failing; excessive crystalloid worsens RV ischemia, left ventricular compression, and cardiovascular collapse. Limit fluid boluses to <=500 mL.
   • Initiate Norepinephrine (or Epinephrine) as the first-line vasopressor to restore coronary perfusion pressure and support RV contractility.
2. Systemic Thrombolytic Therapy:
   • Pregnancy is a relative, not absolute, contraindication to systemic thrombolysis. In life-threatening massive PE with hemodynamic collapse, systemic thrombolysis is life-saving and indicated.
   • Recombinant Tissue Plasminogen Activator (Alteplase / rtPA): 100 mg IV infusion over 2 hours (or 50 mg IV push over 2 minutes in maternal cardiac arrest).
   • UFH infusion should be stopped during thrombolytic infusion and resumed without a bolus when aPTT is <2x control.
   • Prepare for maternal hemorrhage (especially uterine or placental bed bleeding); ensure blood products (PRBCs, FFP, cryoprecipitate, platelets) and intrauterine balloon tamponade are immediately accessible.
3. Catheter-Directed or Surgical Pulmonary Embolectomy:
   • Indicated if systemic thrombolysis is strictly contraindicated (e.g., immediate postpartum hemorrhage, active intracranial bleeding), or if the patient fails to respond to thrombolytic infusion.
4. Perimortem Cesarean Delivery (Resuscitative Hysterotomy):
   • If maternal cardiac arrest occurs in a gravid patient >=20 weeks, initiate CPR with left uterine displacement. If Return of Spontaneous Circulation (ROSC) is not achieved within 4 minutes, perform resuscitative hysterotomy at the 4-minute mark to achieve delivery by minute 5, relieving aortocaval compression and optimizing maternal CPR efficacy.

---

7. Sickle Cell Crisis in Pregnancy (Hematologic Emergency)

Sickle cell crisis is a named topic on the official C-OBE content outline (Domain 2 ▸ Medical Emergencies ▸ Hematological) and appears verbatim in the NCC sample questions, so every candidate should be able to manage an acute vaso-occlusive crisis (VOC) in a parturient without hesitation.

Pathophysiology & Why Pregnancy Escalates Risk

Sickle cell disease (SCD) results from an autosomal-recessive point mutation in the β-globin gene (glutamic acid → valine at position 6), producing hemoglobin S (HbS). Under deoxygenation, acidosis, dehydration, hypothermia, or physical/emotional stress, HbS molecules polymerize into rigid rods that deform the red cell into a sickle shape. Sickled cells:

• Obstruct the microvasculature → vaso-occlusive pain crises and end-organ ischemia
• Hemolyze prematurely → chronic hemolytic anemia (baseline hemoglobin typically 6–9 g/dL in HbSS)
• Damage splenic function early in life → functional asplenia and lifelong susceptibility to encapsulated organisms

Pregnancy markedly increases the frequency and severity of crises — physiologic anemia, hypercoagulability, the oxygen consumption of labor, and peripartum infection all drive sickling. Pregnant patients with SCD face elevated rates of preeclampsia, venous thromboembolism, intrauterine growth restriction, preterm birth, and perinatal mortality in addition to acute crises.

Precipitants to Identify and Treat

Incentive spirometry during hospitalization reduces the progression of a pain crisis to acute chest syndrome (ACS) — a new pulmonary infiltrate with fever, chest pain, hypoxemia, or respiratory distress. ACS is the leading cause of death in SCD and a true obstetric critical emergency; treat with oxygen, broad-spectrum antibiotics (cover atypical organisms), and transfusion.

First-Line Crisis Management: Fluids + Opioid Analgesia

The cornerstone answer the NCC exam expects for acute sickle cell crisis in pregnancy is intravenous fluid resuscitation combined with opioid analgesia:

1. Isotonic IV crystalloid hydration (e.g., normal saline or lactated Ringer's) to restore euvolemia, reduce blood viscosity, and halt sickling.
2. Opioid analgesia is the mainstay of pain control — IV morphine or hydromorphone on a scheduled or patient-controlled regimen. Avoid meperidine (Demerol): its metabolite normeperidine accumulates and lowers the seizure threshold.
3. Avoid NSAIDs, particularly in the third trimester — ketorolac/ibuprofen risk premature closure of the fetal ductus arteriosus and oligohydramnios; local anesthetic infiltration and nonpharmacologic measures are adjuncts, never substitutes, for systemic analgesia.
4. Oxygen when SpO₂ < 95%, continuous maternal monitoring, warmth, and frequent reassessment.

Transfusion Thresholds & Fetal Considerations

• Simple transfusion for symptomatic severe anemia (target hemoglobin ≤ 10 g/dL; over-transfusion raises viscosity); exchange transfusion to rapidly reduce HbS percentage (goal HbS < 30–40%) for acute chest syndrome, stroke, or severe refractory crisis.
• Routine prophylactic transfusion throughout pregnancy is not the default — it is reserved for high-risk courses per maternal-fetal medicine and hematology co-management.
• Hydroxyurea is generally discontinued before conception because of teratogenicity concerns; daily folic acid supplementation supports heightened erythropoiesis.
• Monitor the fetal heart rate continuously during crises in the third trimester; maternal hypoxemia and acidosis produce late decelerations. Correct the maternal physiology first — the tracing usually recovers with maternal stabilization.
• Intrapartum management emphasizes hydration, warmth, oxygenation, and early epidural analgesia (excellent pain control blunts the stress response that precipitates sickling); delivery is typically planned at 36–38 weeks in co-management with MFM.

Exam anchor: NCC sample question — management of sickle cell crisis in a pregnant patient = IV fluid resuscitation + opioid pain control. Distractors built on local anesthetics or NSAIDs are wrong.